We help communities to created a custom knowledge base(still being refined)
Click here to view original web page at www.krqe.com
Albuquerque Neuroscience, Inc. is a local, family-owned clinic that contributes to the development of new treatment for psychiatric illnesses. The clinic is currently conducting a clinical trial on participants with mild to moderate Alzheimer’s disease. Clinical research coordinator Anderson Riddle explains more about this clinical trial. The goal of […]
Click here to view original web page at www.technologynetworks.com
American pharma giant Biogen has announced that its therapeutic compound for Alzheimer’s disease (AD), aducanumab, is to be taken to the FDA for approval. Despite being seemingly killed off after a study in March produced disappointing results, new analysis suggests that aducanumab met its target endpoints. If confirmed, this […]
Click here to view original web page at www.prnewswire.com
New resources detail positive impact of aducanumab pivotal trial results and recent progress of ProMIS pipeline programs TORONTO and CAMBRIDGE, MA, Oct. 24, 2019 /PRNewswire/ – ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF ), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers […]
Click here to view original web page at www.sciencedaily.com
In the years since her lab discovered that exposing Alzheimer’s disease model mice to light flickering at the frequency of a key brain rhythm could stem the disorder’s pathology, MIT neuroscientist Li-Huei Tsai and her team at The Picower Institute for Learning and Memory have been working to understand […]
Click here to view original web page at pipelinereview.com
— Lead compound is an oral small molecule inhibitor of tau aggregation — — The company expects clinical testing to begin in 2021 — CHICAGO, IL, USA I October 22, 2019 I Oligomerix, Inc., a privately held company pioneering the development of tau oligomer inhibitors for Alzheimer’s disease (AD) […]
Click here to view original web page at www.businesswire.com
CHICAGO–( BUSINESS WIRE )–Oligomerix, Inc., a privately held company pioneering the development of tau oligomer inhibitors for Alzheimer’s disease (AD) and related neurodegenerative disorders, presented preclinical data today showing that its orally active, small molecule compound inhibits the earliest steps in the toxic tau aggregation cascade that leads to […]
Click here to view original web page at www.medpagetoday.com
Biogen reversed its take on the anti-amyloid drug aducanumab , saying it will pursue FDA approval for the drug based on a new analysis that showed clinical benefit in treating early Alzheimer’s. Are Alzheimer’s and diabetes linked ? Scientists at the Society for Neuroscience meeting in Chicago look at […]
Click here to view original web page at www.eurekalert.org
CHICAGO — Neuroscientists at Georgetown University Medical Center say they have developed and tested an agent that reduces the buildup of toxic proteins in animal models of both Parkinson’s and Alzheimer’s diseases, and improves cognitive and motor behavior. The team will present their findings about the agent, CM101 (also […]
Click here to view original web page at finance.yahoo.com
CHICAGO–(BUSINESS WIRE)– — Lead compound is an oral small molecule inhibitor of tau aggregation — — The company expects clinical testing to begin in 2021 — Oligomerix, Inc., a privately held company pioneering the development of tau oligomer inhibitors for Alzheimer’s disease (AD) and related neurodegenerative disorders, presented preclinical […]
Click here to view original web page at www.biospace.com
Bicycle to collaborate with ODDI, an organization with deep expertise in the molecular pathology of Alzheimer’s disease and CNS drug development CAMBRIDGE, England & BOSTON–( BUSINESS WIRE )– Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic […]
